CYP2D6-related oxidation polymorphism in a Canadian Inuit population

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 3, 1997, Pages 165-172

  Jurima Romet, Malle ^a   Foster, Brian C ^a   Casley, William L ^a   Rode, Andris ^b   Vloshinsky, Pavel ^c   Huang, Hide S ^a   Geertsen, Susanne ^d  

^a Bureau of Drug Research   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Institute of Biochemistry   (Russian Federation)

^d Pest Management Regulatory Agency   (Canada)

Author keywords

CYP2D6; Dextromethorphan; Genotype; Inuit; Phenotype

Indexed keywords

CAFFEINE; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; MEPHENYTOIN;

ADULT; AGED; CANADA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; DRUG OXIDATION; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030997828     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y97-013     Document Type: Conference Paper

References (51)

1. Agúndez, J.A.G., Ledesma, M.C., Ladero, J.M., and Benítez, J. 1995. Prevalence of the CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57: 265-269.
2. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., and Ingelman-Sundberg, M. 1996. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278: 441-446.
3. Alván, G., Bechtel, B., Iselius, L., and Gundert-Remy, U. 1990. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39: 533-537.
4. Armstrong, M., Fairbrother, K., Idle, J.R., and Daly, A.K. 1994. The cytochrome P450 CYP2D6 allele variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics, 4: 73-81.
5. Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L., and Sjöqvist, F. 1992. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51: 388-397.
6. Bertilsson, L., Dahl, M.-L., Sjoqvist, F., Aberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., and Ingelman-Sundberg, M. 1993. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341: 63.
7. Broly, F., Gaedigk, A., Heim, M., Eichelbaum, M., Morike, K., and Meyer, U.A. 1991. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 10: 545-558.
8. Brøsen, K. 1986. Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br. J. Clin. Pharmacol. 22: 415-419.
9. Brøsen, K., and Gram, L.F. 1989. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 36: 537-547.
10. Clasen, K., Madsen, L., Brøsen, K., Alboge, K., Misfeldt, S., and Gram, L.F. 1991. Sparteine and mephenytoin oxidation genetic polymorphism in East and West Greenland. Clin. Pharmacol. Ther. 49: 624-631.
11. Dahl, M.-L., Yue, Q.-Y., Roh, H.-K., Johansson, I., Säwe J., Sjöqvist, F., and Bertilsson, L. 1995. Genetic analysis of the CYP2D6 locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics, 5: 159-164.
12. Daly, A.K., Armstrong, M., Monkman, S.C., Idle, M.E., and Idle, J.R. 1991. The genetic and metabolic criteria for the assignment of debrisoquine hydroxylation (cytochrome P450IID6) phenotypes. Pharmacogenetics, 1: 33-41.
13. Daly, A.K., Brockmöller, J., Broly, F., Eichelbaum, M., Evans, W.E., Gonzalez, F.J., Huang, J.-D., Idle, J.R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U.A., Nebert, D.W., Steen, M., Wolf, C.R., and Zanger, U.M. 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6: 193-201.
14. Evans, W.E., Relling, M.V., Petros, W.P., Meyer, W.H., Mirro, J., Jr., and Crom, W.R. 1989. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin. Pharmacol. Ther. 45: 568-573.
15. Evans, W.E., Relling, M.V., Rahman, A., McLeod, H.L., Scott, E.P., and Lin, J.-S. 1993. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest. 91: 2150-2154.
16. 1795 in exon 3 generates a premature stop codon. Pharmacogenetics, 4: 271-274.
17. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M., and Meyer, U.A. 1991. Deletion of the entire cytochrome P450 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 48: 943-950.
18. Gough, A.C., Miles, J.S., Spurr, N.K., Moss, J.E., Gaedigk, A., Eichelbaum, M., and Wolf, C.R. 1990. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (London), 347: 773-776.
19. Guttendorf, RJ., and Wedlund, P.J. 1992. Genetic aspects of drug disposition and therapeutics. J. Clin. Pharmacol. 32: 107-117.
20. Guttendorf, R.J., Britto, M., Blouin, R.A., Foster, T.S., John, W., Pittman, K.A., and Wedlund, P.J. 1990. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br. J. Clin. Pharmacol. 29: 373-380.
21. Hadidi, H.F., Cholerton, S., Monkman, S.C., Armstrong, M., Irshaid, Y.M., Rawashdeh, N.M., Daly, A.K., and Idle, J.R. 1994. Debrisoquine 4 hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics, 4: 159-161.
22. 1934 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Hum. Genet. 47: 994-1001.
23. Härtter, S., Baier, D., Diingemanse, J., Ziegler, G., and Hiemke, C. 1996. Automated determination of dextromethorphan and its main metabolites in human plasma by high-performance liquid chromatography and column switching. Ther. Drug Monit. 16: 297-303.
24. Heim, M.H. and Meyer, U.A. 1991. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. In Methods in enzymology. Edited by M.R. Waterman and E.F. Johnson. Academic Press, San Diego, Calif, pp. 173-183.
25. Hildebrand, M., Seifert, W., and Reichenberger, A. 1989. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur. J. Clin. Pharmacol. 36: 315-318.
26. Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H.-H., Zhou, B.-J-, Liao, C.-L., and Zhang, L.-M. 1989. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46: 198-207.
27. Inaba, T., Jurima, M., Nakano, M., and Kalow, W. 1984. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin. Pharmacol. Ther. 36: 670-676.
28. Jacqz-Aigrain, E., Menard, Y., Popon, M., and Mathieu, H. 1989. Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. J. Chromatogr. 495: 361-363.
29. Jacqz-Aigrain, E., Funck-Brentano, C., and Cresteil, T. 1993. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3: 197-204.
30. Johansson, L, Lundqvist, E., Bertilsson, L., Dahl, M.-L., Sjoqvist, F., and Ingelman-Sundberg, M. 1993. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90: 11825 - 11829.
31. Johansson, I., Oscarson, M., Yue, Q.-Y., Bertilsson, L., Sjöqvist, F., and Ingelman-Sundberg, M. 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of the variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46: 452-459.
32. Jorge, L.F., Arias, T.D., Griese, U., Nebert, D.W., and Eichelbaum, M. 1993. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis. Pharmacogenetics, 3: 231-238.
33. Jurima-Romet, M., Goldstein, J.A., LeBelle, M., Aubin, R.A., Foster, B.C., Walop, W., and Rode, A. 1996. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics, 6: 329-339.
34. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., and Meyer, U.A. 1990. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolisers of debrisoquine. J. Biol. Chem. 265: 17209 - 17214.
35. Kiivet, R.A., Svensson, J.-O., Bertilsson, L., and Sjöqvist, F. 1993. Polymorphism of debrisoquine and mephenytoin among Estonians. Pharmacol. Toxicol. 72: 113-115.
36. Li, S., Fried, K., Wainer, I.W., and Lloyd, D.K. 1993. Determination of dextromethorphan and dextrorphan in urine by capillary zone electrophoresis: application to the determination of debrisoquinoxidation metabolic phenotype. Chromatographia, 35: 216-222.
37. Masimirembwa, C.M., Johansson, I., Hasler, J.A., and Ingelman-Sundberg, M. 1993. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics, 3: 275-280.
38. McAlpine, P.J., Chen, S.-H., Cox, D.W., Dossetor, J.B., Giblett, E., Steinberg, A.G., and Simpson, N.E. 1974. Genetic markers in blood in a Canadian Eskimo population with a comparison of allele frequencies in circumpolar populations. Hum. Hered. 24: 114-142.
39. Nakamura, K., Goto, F., Ray, W.A., McAllister, C.B., Jacqz, E., Wilkinson, G.R., and Branch, R.A. 1985. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38: 402-408.
40. Nei, M., and Saitou, N. 1986. Genetic relationship of human populations and ethnic differences in reaction to drugs and food. In Ethnic differences in reactions to drugs and xenobiotics. Edited by W. Kalow, H.W. Goedde, and D.P. Agarwa. Alan R. Liss, New York. pp. 21-37.
41. Price Evans, D.A., Krahn, P., and Narayanan, N. 1995. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics, 5: 64-71.
42. Relling, M.V., Cherrie, J., Schell, M.J., Petros, W.P., Meyer, W.H., and Evans, W.E. 1991. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmcol. Ther. 50: 308-313.
43. Saxena, R., Shaw, G.L., Relling, M.V., Frame, J.N., Moir, D.T., Evans, W.E., Caporaso, N.,and Weiffenbach, B. 1994. Identification of a new variant CYP2D6 single base pair deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet. 3: 923-926.
44. Schmid, B., Bircher, J., Preisig, R., and Küpfer, A. 1985. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther. 38: 618-624.
45. Simpson, N.E., Eriksson, A.W., and Lehmann, W. 1980. Genetic diversity in circumpolar populations. In Population structure and genetic disorders: 7th Sigrid Jus'elius Foundation Symposium, August 1978, Mariehamn, Finland. Edited by A.W. Eriksson. Academic Press, London, pp. 139-149.
46. Sohn, D.-R., Shin, S.-G., Park, C.-W., Kusaka, M., Chiba, K., and Ishizaki, T. 1991. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br. J. Clin. Pharmacol. 32: 504-507.
47. Spina, E., Campo, G.M., Avenoso, A., Caputi, A.P., Zuccaro, P., Pacifici, R., Gatti, G., Strada, G., Bartoli, A., and Perucca, E. 1994. Cyp2D6-related oxidation polymorphism in Italy. Pharmacol. Res. 29: 281-289.
48. Straka, R.J., Hansen, S.R., and Walker, P.F. 1995. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol. Ther. 58: 29-34.
49. Szathmary, E.J.E. 1993. Genetics of aboriginal North Americans. In Evolutionary anthropology. Vol. 1. Wiley-Liss. pp. 202-220.
50. Wang, S.-L., Huang, J., Lai, M.-D., Liu, B.-H., and Lai, M.-L. 1993. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther. 53: 410-418.
51. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kono, I., and Gonzalez, F.J. 1993. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 3: 256-263.